CA3212301A1 - Cell compositions derived from dedifferentiated reprogrammed cells - Google Patents
Cell compositions derived from dedifferentiated reprogrammed cellsInfo
- Publication number
- CA3212301A1 CA3212301A1 CA3212301A CA3212301A CA3212301A1 CA 3212301 A1 CA3212301 A1 CA 3212301A1 CA 3212301 A CA3212301 A CA 3212301A CA 3212301 A CA3212301 A CA 3212301A CA 3212301 A1 CA3212301 A1 CA 3212301A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cell
- heregulin
- cell population
- neuregulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/761,078 US9109245B2 (en) | 2009-04-22 | 2013-02-06 | Cell compositions derived from dedifferentiated reprogrammed cells |
| US13/761,078 | 2013-02-06 | ||
| CA2898431A CA2898431C (en) | 2013-02-06 | 2014-02-06 | Cell compositions derived from dedifferentiated reprogrammed cells |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2898431A Division CA2898431C (en) | 2013-02-06 | 2014-02-06 | Cell compositions derived from dedifferentiated reprogrammed cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3212301A1 true CA3212301A1 (en) | 2014-08-14 |
Family
ID=50239931
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3212301A Pending CA3212301A1 (en) | 2013-02-06 | 2014-02-06 | Cell compositions derived from dedifferentiated reprogrammed cells |
| CA2898431A Active CA2898431C (en) | 2013-02-06 | 2014-02-06 | Cell compositions derived from dedifferentiated reprogrammed cells |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2898431A Active CA2898431C (en) | 2013-02-06 | 2014-02-06 | Cell compositions derived from dedifferentiated reprogrammed cells |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2954045A1 (https=) |
| JP (5) | JP6517702B2 (https=) |
| AU (5) | AU2014214879A1 (https=) |
| CA (2) | CA3212301A1 (https=) |
| HK (1) | HK1218139A1 (https=) |
| IL (5) | IL311689B2 (https=) |
| RU (2) | RU2754089C2 (https=) |
| WO (1) | WO2014124172A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| EP3178924B1 (en) | 2014-08-04 | 2019-12-25 | Takeda Pharmaceutical Company Limited | Method for proliferation of pancreatic progenitor cells |
| US10420803B2 (en) * | 2016-04-14 | 2019-09-24 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells to intestinal midgut endoderm cells |
| CN111349604B (zh) | 2016-05-18 | 2023-12-12 | 学校法人庆应义塾 | 类器官培养用细胞培养基、培养方法及类器官 |
| KR102448428B1 (ko) | 2017-01-27 | 2022-09-30 | 가부시키가이샤 가네카 | 내배엽계 세포 집단, 및 다능성 세포로부터 3배엽 중 어느 하나의 세포 집단을 제조하는 방법 |
| CN111565707A (zh) | 2017-06-14 | 2020-08-21 | 森玛治疗公司 | 用于递送治疗物的装置和方法 |
| CN111246864A (zh) * | 2017-07-21 | 2020-06-05 | 森玛治疗公司 | 干细胞衍生的胰腺β细胞的重聚 |
| EP3831931B1 (en) * | 2018-08-03 | 2025-04-09 | Orizuru Therapeutics, Inc. | Cell production method |
| WO2020059892A1 (ja) * | 2018-09-19 | 2020-03-26 | 武田薬品工業株式会社 | インスリン産生細胞 |
| CA3139292C (en) | 2019-05-31 | 2025-06-10 | Viacyte, Inc. | CELL ENCAPSULATION DEVICES WITH REGULATED OXYGEN DIFFUSION DISTANCES |
| EP3976236A1 (en) | 2019-05-31 | 2022-04-06 | W.L. Gore & Associates Inc. | A biocompatible membrane composite |
| CN114173837A (zh) | 2019-05-31 | 2022-03-11 | W.L.戈尔及同仁股份有限公司 | 生物相容性膜复合材料 |
| EP3975926A1 (en) | 2019-05-31 | 2022-04-06 | W.L. Gore & Associates, Inc. | A biocompatible membrane composite |
| WO2022026932A2 (en) | 2020-07-31 | 2022-02-03 | Vertex Pharmaceuticals Incorporated | Differentiation of pancreatic endocrine cells |
| US20260097083A1 (en) * | 2022-09-26 | 2026-04-09 | Kyoto University | Method for producing pancreatic endoderm cells |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4209300A (en) * | 1999-04-06 | 2000-10-23 | Genentech Inc. | Use of erbb receptor ligands in treating diabetes |
| US6759039B2 (en) * | 2000-06-30 | 2004-07-06 | Amcyte, Inc. | Culturing pancreatic stem cells having a specified, intermediate stage of development |
| EP1366148A2 (en) * | 2001-01-24 | 2003-12-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Differentiation of stem cells to pancreatic endocrine cells |
| CN101310012B (zh) * | 2005-10-14 | 2012-05-09 | 明尼苏达大学董事会 | 非胚胎干细胞分化成具有胰腺表型的细胞 |
| US20090298169A1 (en) * | 2006-06-02 | 2009-12-03 | The University Of Georgia Research Foundation | Pancreatic and Liver Endoderm Cells and Tissue by Differentiation of Definitive Endoderm Cells Obtained from Human Embryonic Stems |
| JP2012508584A (ja) * | 2008-11-14 | 2012-04-12 | ヴィアサイト，インコーポレイテッド | ヒト多能性幹細胞由来膵臓細胞のカプセル化 |
| EP2421957B1 (en) * | 2009-04-22 | 2020-11-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| US9109245B2 (en) * | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| CN107603943B (zh) * | 2009-04-27 | 2019-10-11 | 威盛细胞有限公司 | 支持多能细胞生长的小分子和其方法 |
| EP2436397B1 (en) * | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
-
2014
- 2014-02-06 IL IL311689A patent/IL311689B2/en unknown
- 2014-02-06 CA CA3212301A patent/CA3212301A1/en active Pending
- 2014-02-06 WO PCT/US2014/015156 patent/WO2014124172A1/en not_active Ceased
- 2014-02-06 EP EP14708981.7A patent/EP2954045A1/en active Pending
- 2014-02-06 AU AU2014214879A patent/AU2014214879A1/en not_active Abandoned
- 2014-02-06 JP JP2015556262A patent/JP6517702B2/ja active Active
- 2014-02-06 RU RU2018144412A patent/RU2754089C2/ru active
- 2014-02-06 IL IL321825A patent/IL321825A/en unknown
- 2014-02-06 CA CA2898431A patent/CA2898431C/en active Active
- 2014-02-06 HK HK16106057.9A patent/HK1218139A1/zh unknown
- 2014-02-06 IL IL290717A patent/IL290717B2/en unknown
- 2014-02-06 RU RU2015131279A patent/RU2675928C2/ru active
-
2015
- 2015-07-15 IL IL239953A patent/IL239953B/en active IP Right Grant
-
2019
- 2019-02-26 AU AU2019201314A patent/AU2019201314B2/en active Active
- 2019-04-18 JP JP2019078983A patent/JP6721752B2/ja active Active
-
2020
- 2020-06-18 JP JP2020104982A patent/JP7250731B2/ja active Active
-
2021
- 2021-05-10 IL IL283088A patent/IL283088B/en unknown
-
2022
- 2022-01-07 AU AU2022200075A patent/AU2022200075C1/en active Active
- 2022-10-27 JP JP2022172222A patent/JP7550830B2/ja active Active
-
2023
- 2023-04-26 AU AU2023202507A patent/AU2023202507B2/en active Active
-
2024
- 2024-09-03 JP JP2024151116A patent/JP2025000625A/ja active Pending
-
2026
- 2026-03-02 AU AU2026201562A patent/AU2026201562A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240409900A1 (en) | Cell encapsulation device comprising a pancreatic progenitor cell population | |
| AU2023202507B2 (en) | Cell compositions derived from dedifferentiated reprogrammed cells | |
| AU2023201602B2 (en) | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells | |
| EP2421957B1 (en) | Cell compositions derived from dedifferentiated reprogrammed cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230908 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250131 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250131 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250131 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250415 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250415 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250505 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250513 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250513 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250610 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250924 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250924 |